Mizuho Maintains Outperform on Insmed, Raises Price Target to $206

Benzinga Newsdesk www.benzinga.com Positive 92.3%

Neg 0% Neu 0% Pos 92.3%

Mizuho analyst Graig Suvannavejh maintains Insmed (NASDAQ:INSM) with a Outperform and raises the price target from $204 to $206.